clinical trial · NCT07297979
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Ewing SarcomaXaluritamig
brief summary
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
started
Apr 8, 2026
primary completion
May 26, 2030
completion
May 26, 2030
last updated
Jun 11, 2026
official title
A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Xaluritamig in Adult, Adolescent and Pediatric Participants With Relapsed or Refractory Ewing Sarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol